• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MDS Completes Sale of Discovery, Preclinical Portion of CRO

MDS Completes Sale of Discovery, Preclinical Portion of CRO

March 9, 2010
CenterWatch Staff

MDS completed its sale of the discovery and preclinical business of MDS Pharma Services, the company’s contract research organization (CRO).  Under the terms of the deal, CRO Ricerca Biosciences of Concord, Ohio, acquired facilities in Bothell, Wash.; Lyon, France; and Taipei, Taiwan. Those facilities have 600 employees.

Ricerca is an early-stage CRO with capabilities in discovery and medicinal chemistry, API process chemistry, cGMP manufacturing and scale-up, and IND-enabling toxicology. MDS Pharma will add molecular profiling, pharmacology/DMPK and drug safety assessment to its list of services.

MDS is selling the remainder of its CRO business—the development and regulatory services consultancy as well as five early-stage facilities in Ireland, Nebraska, New Jersey, Arizona and Switzerland—to a new corporation primarily owned by private investment firms Bain Capital Ventures and SV Life Sciences. That sale is expected to close by the end of April. According to published reports, the total of both deals is approximately $45 million.

Neither deal includes the sale of MDS Pharma’s King of Prussia, Pa., executive office or its early clinical research and bioanalysis operations in Montreal, Quebec. The Pennsylvania office closed earlier this year, and the Montreal operations will be decommissioned over the next year with final close occurring in early 2011. Approximately 225 employees will be laid off as a result of the closures, while another 50 jobs will be eliminated from MDS Pharma Services’ other locations.

 

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing